Production Of GSK's Ziagen HIV Oral Liquid Medicine

GlaxoSmithKline Canada Inc. employees package bottles of Ziagen, an HIV oral liquid medication, on the packaging line at the company's Canadian headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images
GlaxoSmithKline Canada Inc. employees package bottles of Ziagen, an HIV oral liquid medication, on the packaging line at the company's Canadian headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images
Production Of GSK's Ziagen HIV Oral Liquid Medicine
ACQUISTA UNA LICENZA
Come posso utilizzare questa immagine?
475,00 €
EUR

DETTAGLI

Restrizioni:
Contatta l'ufficio locale per informazioni su qualsiasi tipo di uso commerciale o promozionale.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Attestazione:
Bloomberg / Collaboratore
N. Editorial:
107630294
Collezione:
Bloomberg
Data di creazione:
13 dicembre 2010
Data di upload:
Tipo di licenza:
Info sulla liberatoria:
Senza liberatoria. Ulteriori informazioni
Fonte:
Bloomberg
Nome oggetto:
GLAXO